Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tunlametinib: First Approval.

Drugs - 1 Aug 2024

Keam Susan J

Abstract excerpt

Tunlametinib (®) is an oral, selective, mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) inhibitor being developed by Shanghai KeChow Pharma, Inc. for the treatment of solid tumours with RAS and RAF mutations, including melanoma, non-small cell cancer (NSCLC), colorectal cancer (CRC) and neurofibromatosis type 1 (NF1) plexiform neurofibromas. In March 2024, tunlametinib was granted conditional approval...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Approval

Share to MAP Kinase Kinase 1

Share to Melanoma

Share to Neoplasms

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 39034326
DOI: 10.1007/s40265-024-02072-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tunlametinib: First Approval.PMID 39034326Read ↗

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read ↗

Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation.Semantic proximity Read ↗

Sugemalimab: First Approval.Semantic proximity Read ↗

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.Semantic proximity Read ↗

First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.Semantic proximity Read ↗

FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions.Semantic proximity Read ↗

Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1.Semantic proximity Read ↗

Tovorafenib: First Approval.Semantic proximity Read ↗

Lonafarnib: First ApprovalSemantic proximity Read ↗

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 TrialsSemantic proximity Read ↗

Avutometinib and Defactinib: First Approval.Semantic proximity Read ↗

Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.